Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simtuzumab with Gemcitabine in Metastatic Pancreatic Cancer
NCT01472198Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2011
- Primary completion
- Oct 2013
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of simtuzumab in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Gilead Sciences. Primary endpoint: Progression-Free Survival at 3 years. Started Nov 2011; status: completed.
02
Drugs
simtuzumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01472198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01472198.